Insider filing · AARD

Tien-Li Lee bought $265K of Aardvark Therapeutics (AARD)

Executed Feb 14 2025, disclosed Feb 19 2025, 5 days later.

Over the 21 trading sessions from the disclosed entry session (Feb 19 2025), the stock returned -29.2% (delay-adjusted); from the execution session (Feb 14 2025), -35.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

TL Tien-Li Lee Chief Executive Officer profile →

Tien-Li Lee (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Aardvark Therapeutics, Inc. (AARD). Across 1 priced purchase filing, the average 21-session return was +3.1% from execution and -3.6% from disclosure (delay-adjusted; derived). The largest single filing was $101K of AARD (7,000 sh × $14.48, as filed), executed Dec 11 2025.

AARD Aardvark Therapeutics, Inc. AARD · Healthcare · 6 filings in 24 months ticker →

Healthcare · Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate inna…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→